FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Press Releases / Read Press Release

Print

MidCap Equity Partners Makes Growth Investment in MoleSafe

November 17, 2017, 07:00 AM
Filed Under: Healthcare


In support of MoleSafe's continuing rapid growth, MidCap Equity Partners, LLC, in conjunction with management and industry experts, have invested in MoleSafe, a telehealth leader in advanced skin screening diagnostic services.

"MoleSafe is partnering with top rated hospitals and other facilities around the country to provide its Skin Surveillance Program ('SSP'). This investment will enable our company to continue expanding operations and make MoleSafe available to patients across the country," stated Kevin Sheridan, CEO, MoleSafe.

MoleSafe's SSP is a proprietary suite of advanced melanoma detection and diagnostic tools and technology, including total body photography, digital dermoscopy, and digital serial monitoring that produces high-resolution diagnostic images and creates a profile of a patient's skin. This profile is monitored by experts for any changes in lesions over time. This enables reliable accuracy to detect skin cancer and melanoma at the earliest possible stage for fast, effective treatment.

MidCap's co-founder, John Poppe, Jr. said, "We are excited about this investment from several standpoints. First, it is an excellent diagnostic service in support of dermatologists who value the comprehensive digital benchmarking that MoleSafe provides. Second, MoleSafe's technology reduces healthcare costs significantly. Third, the technology platform enables expert remote access to assist with recommending a course of care. Fourth, Kevin and his team are growing the company rapidly and attracting an impressive investor base."

"One in five Americans will develop skin cancer over the course of their lifetime, and unlike many other forms of cancer, the incidence of skin cancer has continued to increase annually.  Each year over 3.3 million people are treated for skin cancer. Our SSP system is designed to assist dermatologists by exposing layers of skin lesions not typically viewed during a regular exam," Sheridan explained.

"We look forward to working with Kevin and the MoleSafe team as the company continues to grow and provide important early detection and diagnostic services to clients around the country," concluded Poppe.







Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.